Skip to main content
Premium Trial:

Request an Annual Quote

Barney Saunders

Purigen Biosystems has named Barney Saunders as its new CEO and a member of the board of directors. Saunders joins the Pleasanton, California-based nucleic acid sample prep firm from NanoString Technologies, where he served as SVP of sales and marketing, SVP and GM of life sciences, and chief commercial officer. He also previously served as chief commercial officer of Microchip Biotechnologies (which became IntegenX), and as a general manager at Agilent Technologies, where he led the team that launched the first commercially available full genome arrays for human, rat, and mouse.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.